Research Progress on Improving the Efficiency of CDT by Exacerbating Tumor Acidification

Wenting Chen¹, Jinxí Li¹, Caiyun Zheng¹, Que Bai¹, Qian Gao¹, Yanli Zhang¹, Kai Dong², Tingli Lu¹

¹Key Laboratory for Space Biosciences and Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi’an, 710072, People’s Republic of China; ²School of Pharmacy, Xi’an Jiaotong University, Xi’an, 710072, People’s Republic of China

Correspondence: Tingli Lu, Key Laboratory for Space Biosciences and Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi’an, 710072, People’s Republic of China, Tel/Fax +86 29 8846 0332, Email lutinglixin@nwpu.edu.cn; Kai Dong, School of Pharmacy, Xi’an Jiaotong University, Xi’an, 710072, People’s Republic of China, Tel/Fax +86 29-82655139, Email dongkai120@xjtu.edu.cn

Abstract: In recent years, chemodynamic therapy (CDT) has received extensive attention as a novel means of cancer treatment. The CDT agents can exert Fenton and Fenton-like reactions in the acidic tumor microenvironment (TME), converting hydrogen peroxide (H₂O₂) into highly toxic hydroxyl radicals (·OH). However, the pH of TME, as an essential factor in the Fenton reaction, does not catalyze the reaction effectively, hindering its efficiency, which poses a significant challenge for the future clinical application of CDT. Therefore, this paper reviews various strategies to enhance the antitumor properties of nanomaterials by modulating tumor acidity. Ultimately, the performance of CDT can be further improved by inducing strong oxidative stress to produce sufficient ·OH. In this paper, the various acidification pathways and proton pumps with potential acidification functions are mainly discussed, such as catalytic enzymes, exogenous acids, CAIX, MCT, NHE, NBCn1, etc. The problems, opportunities, and challenges of CDT in the cancer field are also discussed, thereby providing new insights for the design of nanomaterials and laying the foundation for their future clinical applications.

Keywords: chemodynamic therapy, Fenton/Fenton-like reactions, tumor microenvironment, reactive oxygen species

Introduction

Chemodynamic therapy (CDT) has been a novel method in tumor treatment in recent years.¹² CDT utilizes the characteristics of relatively low pH and high endogenous H₂O₂ in the tumor microenvironment (TME),³ and some transition metal ions, such as Fe²⁺, Mn²⁺, can act as catalysts to accelerate the Fenton-like reaction of H₂O₂ to produce the ·OH, which will kill tumor cells by oxidizing the lipids, nucleic acids, proteins and other biological molecules (Figure 1).⁴⁻⁸ Its excellent therapeutic effect on tumors has been verified in laboratory studies.⁹ Chemotherapy and radiotherapy, as treatments for cancer, have serious side effects, including toxicity and immunosuppression, which limit their anti-tumor efficacy and increase the risk of infection.¹⁰¹¹ Compared to them, CDT agents are less prone to serious side effects and drug resistance. Simultaneously, there is no need to be limited by oxygen and near-infrared light (NIR) as that of photothermal therapy (PTT) or photodynamic therapy (PDT). It can use the unique microenvironment in the tumor to produce oxidative stress reaction, realize the specificity and efficiency of tumor treatment, and reduce the damage to normal cells or tissues.¹² As a new way of cancer treatment, CDT can solve some drawbacks of traditional cancer therapy to a certain extent.

Although CDT has excellent prospects, there are still some challenges in the therapeutic effect of CDT agents.¹³ The main influencing factors are as follows. First, endogenous H₂O₂ (50–100 μM) in tumor cells is difficult to support the continuous production of ·OH, which is insufficient to achieve numerous killing effects on tumor cells.¹⁴¹⁵ Second, the concentration of glutathione (GSH) in normal cells is about 1–2 mM, but its concentration can reach 10 mM in cancer cells.¹⁶¹⁷ So, a large amount of reduced GSH produced in TME will remove ·OH and reduce oxidative stress, resulting in the obstacles to CDT.¹⁸¹⁹ CDT is highly dependent on Fenton reaction, which has high requirements for the biological microenvironment, a solid acidic with pH 2–4.²⁰ pH responsive nanoparticles can effectively release iron ions from
nanocarriers to a certain extent in the acidic microenvironment of tumors with low pH. Subsequently, iron ions are effectively converted into highly active •OH by Fenton reaction for CDT. Whereas the extracellular pH (pHe) of TME is only about 6.8 and the intracellular (pHi) is approximately 7.2, which is higher than that of the Fenton reaction (pH 2–4). Therefore, due to the heterogeneity of tumor histopathology and physiology, it is expected to develop more active strategies of tissue microenvironment reprogramming through nanotechnology to improve the performance of CDT, which provides the compelling impetus for the Fenton reaction.

Increasing intracellular acidification is an effective way to enhance the Fenton reaction and efficacy of CDT. Tumor microenvironment reprogramming is essential for improving the responsiveness and performance of nanomedicines. Accelerating the formation of acid and inhibiting the efflux of intracellular lactate/H⁺ all can reduce the pH value of tumor. For instance, producing acid by enzyme catalysis, introducing photoacid in tumor, and production of H⁺ by mitochondrial respiratory complex enzyme inhibitor, all can accelerate acid formation. According to inhibiting the efflux of intracellular lactate/H⁺, pHe was indirectly reduced by inhibiting various proton pumps on the surface of the cell membrane and blocking the efflux of lactic acid. In this review, we focus on two perspectives to reduce intracellular pH, accelerating acid formation and inhibiting the efflux of intracellular lactate/H⁺. We also discuss the inhibitors of different proton pumps, which provide a new perspective for the design of subsequent nanoparticles to realize the acidification function.
Accelerate Acid Formation
Use of Catalytic Enzymes
A Low level of pH value is considered to be the critical factor for the efficacy of CDT in tumors.²⁷ It is believed that there are more glucose and amino acids in tumor tissue for its rapid proliferation, and gluconic acid and α-keto acid are their oxidation products, which are conducive to reducing pH value.²⁸,²⁹ The catalytic mechanism is shown in Figure 2.

GOx-Instructed pH Regulation
Glucose is an indispensable energy source in cells.³⁰ Compared with normal cells, rapid proliferating cancer cells will consume more glucose to produce more energy, so they are highly sensitive to changes in the level of glucose.³¹–³³ Glucose in TME will convert to gluconic acid and H₂O₂ by introducing exogenous glucose oxidase (GOx), which is often used as one of the ways of tumor starvation therapy.³⁴,³⁵ Among them, gluconic acid can provide appropriate acidic conditions for the Fenton reaction. Similarly, acidification can also further decompose the nano-delivery system and promote the cascade reaction.³⁶ Thus, it is worth noting that the Fenton reaction induced by glucose acidification is a promising strategy of cancer therapy.

Glucose acid is widely considered as a promoter to improve Fenton reaction efficiency. A nanoscale Co-ferrocene metal-organic framework (Co-Fc NMOF) with high Fenton activity was synthesized by research group of Fang, and then combined with glucose oxidase (GOx) to construct a cascade enzymatic/Fenton catalytic platform (Co-Fc@GOx) for strengthening tumor treatment.³⁷ In this system, Co-Fc-NMOF acted as an effective carrier of GOx and could produce highly toxic ·OH with a good Fenton effect. When this system reached the tumor microenvironment, GOx would catalyze the endogenous glucose to produce gluconic acid and H₂O₂. Both the increase of intracellular acidity and H₂O₂ content in situ were conducive to the Fenton reaction of Co-Fc-NMOF, which would further promote the generation of ROS in the local tumor site. In 4T1 tumor-bearing mice, it was found that the tumor volume in the treated group was smaller than that in the control, showing the tumor inhibition by Co-Fc-NMOF introduced. It was noteworthy that the most significant antitumor effect could be obtained with Co-Fc
@GOx treated through the cascade enzyme/Fenton reaction. The authors also found that GOx alone had a limited inhibitory effect on tumor growth, which could be attributed to its diffusion and degradation in tumor tissues. Therefore, the appropriate nanocarriers were essential for the load and protection of GOx, which also could greatly avoid the damage of GOx to the normal tissues. Additionally, a kind of block copolymers was prepared by research group of Li, which was composed of poly(ethylene glycol) (PEG) and copolymerized monomers of camptothecin (CPT) and piperidine-modified methacrylate [P(CPTMA-co-PEMA)]. It could self-assemble into polymer vesicles in aqueous solution for encapsulation of GOx. 

Vesicle structure had good integrity and stability in the process of intracellular action, so as to protect GOx from harsh environment and maintain long-term activity. Therefore, it was concluded that GOx could provide a potential therapeutic platform for tumor collaborative therapy and effectively regulate the tumor microenvironment.

The efficiency of GOx catalytic reaction is strongly dependent on oxygen concentration, but the hypoxia condition in TME leads to low activity of GOx. In order to overcome this problem, a dual-catalytic nanoreactor with oxygen-containing support was prepared by research group of Zhang. Hollow mesoporous silica nanoparticles (HMSNs) were used to load Fe$_3$O$_4$ nanoparticles as the Fenton reaction catalyst and GOx as the glucose oxidation catalyst on the HMSN surface. The oxygen-carrying perfluorohexane (PFC), acting as an oxygen carrier, was encapsulated in the pores of HMSNs. Finally, the cancer cell membrane was coated on the nanoreactor to construct the final GOx-Fe$_3$O$_4$-HMSNs-PFC/O$_2$@C. The results showed that GOx effectively consumed glucose in tumor and increased the generation of H$_2$O$_2$, which was further reacted with Fe$_3$O$_4$. Based on this, the Fenton reaction was enhanced and led to the increased production of highly toxic ·OH and the apoptosis of cancer cells in the end. For the hypoxia in the tumor microenvironment, PFC, containing an extensive amount of O$_2$, could improve the catalytic efficiency of GOx, increase the production of glucuronic acid and H$_2$O$_2$, and provide a suitable condition for the activation of CDT by Fenton reaction in the next step. In addition, treated with GOx-Fe$_3$O$_4$-HMSNs-PFC/O$_2$@C obtained higher tumor inhibition effect compared with other treatment groups in vivo. Take the life span of mice for example, the mice treated with Fe$_3$O$_4$-HMSNs-PFC/O$_2$@C was survived only for 13 days, greatly reduced about 17 days of that in control. These results might be attributed to the synergistic inhibitory effect of Fe$_3$O$_4$ nanoparticles, GOx, and O$_2$ against tumor, as well as the significant efficacy of GOx in Fenton-mediated CDT.

In situ decomposition of H$_2$O$_2$ into O$_2$ in tumor cells by catalase-active nanozymes is also an important strategy for reoxygenation. A multi-functional nanoreactor Fe–MIL-88B–NH$_2$@PFC-1-GOx (MPG), based on MOFs (Fe–MIL
-88B-NH$_2$), hydrogen-bonded organic frameworks (PFC-1), and GOx, was reported by Hu. Here, the function of GOx was like the previous report. It has been proved that gluconic acid can not only provide an appropriate pH for the Fenton reaction but also promote the decomposition and release of the acid sensitive nano-delivery system. The mesoporous iron oxide nanoparticles (IONP) were firstly modified by GOx, and then the artemisinin (ART) was loaded to design a cascade catalytic nanoplatform IONP-GOx@ART. Glucose oxidation was catalyzed by GOx and gluconic acid and H$_2$O$_2$ were produced, resulted in the tumor starvation and the activity of IONP-mediated Fenton reaction. The more acidic TME based on the gluconic acid generated was helpful for the release of Fe$^{2+}$ and Fe$^{3+}$ ions, which could generate ·OH through the Fenton reaction. In addition, the presence of Fe$^{2+}$ would lead to destroy of the endoperoxide bridge in ART molecule, which caused the high level of ROS. All of the above results were benefit to CDT. This effect was again proved in 4T1 tumor-bearing mice, the tumor growth of treated by IONP-GOx@ART was significantly inhibited compared with that of IONP@ART, demonstrating the great potential of GOx in anti-tumor therapy.

In short, GOx has been widely used in CDT, which provides a bright prospect for the anti-tumor treatment of CDT. The unique chemical reaction of GOx in tumor and its diversified applications make it a priority to regulate the acidic microenvironment of tumor. GOx can produce gluconic acid and abundant H$_2$O$_2$, which provides sufficient reactants for the Fenton reaction. So, GOx can regulate TME and provide a new idea for the treatment of malignant tumors. However, free GOx tends to overflow before reaching the tumor site and get the nonspecific accumulation in normal tissues, which inevitably limited the efficiency of CDT and enhanced its cytotoxicity. Therefore, the selection of nanocarriers is very important, which can be supported by MOF, mesoporous silica, or modified by chemical bonds. Since the catalytic reaction of GOx only works in the presence of O$_2$, it is imperative to provide sufficient O$_2$ to alleviate the hypoxic environment of the tumor, as well as to improve the catalytic efficiency of GOx.

**L-Amino Acid Oxidase-Instructed pH Regulation**

Amino acid (AA), a monomer for protein synthesis, is an important nutrient for the proliferation of cells, and it is also necessary for the survival of cells. In addition, AA is also an essential substance in the biosynthesis of lipids, nucleotides, and other substances. Therefore, the proliferation of tumor cells needs more AAs in response to meet the needs of the increased cell anabolism and rapid growth. However, L-amino acid oxidase (AAO) can catalyze the oxidation of amino acids to produce α-keto acids, releasing hydrogen peroxide and ammonia. Among them, α-keto acid is helpful to adjust the pH value of tumor and promote Fenton or Fenton-like reaction, and H$_2$O$_2$ can also continuously provide the substrates for Fenton reaction.

Research groups of Chu grafted L-Amino acid oxidase (AAO) on the surface of the hollow Fe$^{3+}$/tannic acid nano capsules (HFe-TA), and covered 4T1 cancer cell membrane to form M@AAO@HFe-TA. In this system, AAO significantly consumed amino acids after entering cancer cells and produced α-keto acids and H$_2$O$_2$ to promote the formation of ·OH in HFe-TA. The cancer cell membrane on the surface of nanocapsules played a protective role in preventing AAO exposure and its potential cytotoxicity. Meanwhile, nanoparticles with certain immune escape and tumor targeting abilities could be got by the surface modification with the cancer cell membrane. Hence, this study might provide a new method to treat tumors and improve its biosafety and efficiency.

**Photoacid-Instructed pH Regulation**

Photoacid can produce H$^+$ and reduce pH value under light stimulation. Most of photoacid are the aromatic organic molecules and the weak acid in the ground electronic state. While in the first excited electronic state, they will generate a larger order of magnitude of H$^+$. The irradiated photoacid is expected to realize the remote space and time control of proton dissociation, and also realize the conversion of light energy into other types of energy. It has been confirmed that some phenolic derivatives, such as phenols and naphthols, can significantly increase acidity under light irradiation. At present, photoacid has been used as part of nanomaterials to improve the efficiency of CDT (Figure 3).
Research groups of Chen designed a near infrared light (NIR)-controlled nano-proton supplier, whose upconversion nanoparticles (UCNPs) were used as the core of the MIL-88B coating for internal photoacids (PA) loading (UCNP @ MIL-88B @ PA, abbreviated as UMP). It was verified that the emission light of UCNPs under 980 nm laser irradiation could activate PA molecules cyclization to release $\text{H}^+\text{.}$ When UMP penetrated the cytoplasm of tumor cells, rapid dissociation of protons led to the decrease of the intracellular pH value. Under increasingly strong acidic conditions, the catalytic active sites Fe in the MIL-88B shell could effectively react with $\text{H}_2\text{O}_2$ to enhance the therapeutic effect of CDT on tumors. Therefore, all reliable evidence shows that PA can release $\text{H}^+$ under the control of light and play an effective role in CDT.

In summary, PA can specifically increase the $\text{H}^+$ concentration in TME under the control of specific light, but have almost no effect on the normal cells, with good biocompatibility. Therefore, the introduction of PA can significantly enhance the efficiency of Fenton/Fenton-like reactions and tumor treatment.

**Inhibitor of Mitochondrial Complex I-Instructed pH Regulation**

Mitochondrial respiration is the basis of normal metabolism in most mammalian cells, which provides a central mechanism for coupling fuel and oxygen consumption with ATP synthesis. $^{54}$ According to previous studies, mitochondrial dysfunction will affect tumorigenesis. $^{55}$ Mitochondrial complex I. is called a reduced nicotinamide adenine dinucleotide (NADH)-ubiquinone oxidoreductase (Q reductase), which can catalyze the NADH oxidation in the electron transport chain. $^{56}$ Complex I has a great impact on cell respiration and metabolic reprogramming and oxidative stress in a variety of malignant tumors (Figure 4). However, inhibitors of mitochondria complex I can reduce the mitochondrial respiration and ATP production, and promote cancer cells to adopt glycolysis resulting in higher lactate levels. $^{57}$ Therefore, complex I inhibitors are important in oncology research. $^{58}$

The research group of Shi developed a nanoplatform (FePt@FeOx@TAM-PEG) that could achieve efficient and specific anti-cancer effect through a dual pathway of cyclic amplification strategy. Tamoxifen (TAM), an inhibitor of mitochondrial complex I, could enhance glycolysis and lactate content, leading to the intracellular $\text{H}^+$ accumulation and overcoming the limitation of TME. Owing to the continuous cyclic release process, more FePt@FeOx were activated via a dual pathway of positive feedback loop, which would induce the strong ROS accumulation within cancer cells and lead to the significant increase of oxidative stress and apoptosis. Notably, the pH-responsive characteristics of TAM allowed
the FePt@FeOx to be “turn on” in acidic TME, but keep “turn off” under neutral conditions. Therefore, it is of great significance to further strengthen tumor therapy by reprogramming TME.

Inhibitors of mitochondrial complex I play an essential role in enhancing the effect of CDT. So, it is crucial to find new inhibitors of mitochondrial complex I. The research group of Ju confirmed that the anti-cancer drug carboxyamidotriazole (CAI) could inhibit mitochondrial respiration in cancer cells and enhance its anti-cancer activity by further regulating energy metabolism. When it was incubated with cancer cells, it could stimulate glucose uptake and lactate production, and inhibit oxidative phosphorylation (OXPHOS) in cancer cells, resulting in a decrease in the activity of the respiratory chain complex I. This result could lead to the lack of ATP production in mitochondria and force tumor cells to up-regulate glycolysis, leading to the increase of lactic acid. In addition, META-IOD-BENZYLGUANIDINE (MIBG) could also inhibit the complex I of the mitochondrial respiratory chain. Related experiments showed that a progressive increase of the lactate was observed after incubation of the cells with glucose and rising concentration of MIBG.

In conclusion, TAM, CAI and MIBG can influence mitochondrial respiration, up-regulate glycolysis and increase lactic acid content. Thus, they are expected to combine with CDT to efficiently treat cancer.

Inhibited the Efflux of Intracellular Lactate/H⁺

The acidic microenvironment is an important condition for promoting treatment of CDT. At present, the main proton pumps and proteins involved in tumor pH regulation are carbonic anhydrase IX (CAIX), monocarboxylate transporters (MCT), Na⁺/H⁺ exchanger (NHE), Na⁺-HCO₃⁻ cotransporter (NBCn1) and so on, and its regulation mechanism is showed in Figure 5. These inhibitors can regulate the activity of these proton pumps and proteins to inhibit the efflux of intracellular lactate/H⁺ and acidify the TME, which is more conducive to the occurrence of Fenton reaction. So far, some proton pumps and protein inhibitors have been widely reported and achieve the excellent therapeutic effects in inhibiting H⁺ efflux (Table 1).

CA IX-Instructed pH Regulation

Carbonic anhydrase is widely distributed in mammalian cells, mainly in the cytoplasm (CA I, CA II, CA III, CA VII and CA XIII), mitochondria (CA VA and CA VB), membrane (CA IV, CA IX, CA XII, CA XIV and CA XV). Some carbonic anhydrase isoenzymes (CA II, CA IX and CA XII) are closely related to tumorigenesis, especially CA IX. Carbonic anhydrase IX (CAIX) is a zinc-containing transmembrane metalloenzyme. Carbon dioxide is also a key source of acid in
tumors. CAIX can catalyze the conversion of CO$_2$ into bicarbonate and H$^+$ (CO$_2$ + H$_2$O $\rightleftharpoons$ HCO$_3^-$ + H$^+$), which will stabilize intracellular pH value and enhance the extracellular matrix decomposition and cell invasion. The structure of carbonic anhydrase has been widely studied. For instance, the CA IX protein (called MN or G250) detected in HeLa cells, contains an N-terminal proteoglycan-like domain, a CA domain, a transmembrane anchor, and a C-terminal cytoplasmic tail. It is upregulated in tumor cells under hypoxic conditions. The accumulation of hypoxia-inducible factor-1α induces the expression of CAIX and causes a variety of downstream effects, including acidification of the extracellular, loss of cellular adhesion, and increased tumor cell migration. Therefore, CA IX has been recognized as a valuable target for cancer diagnosis and treatment because of its unique property in hypoxic TME.

Fortunately, these special physiological processes can be reverted by inhibiting the activity of the CA IX enzyme through carbonic anhydrase IX inhibitor (CAI). Chen proposed a self-enhanced CDT to inhibit tumor occurrence and metastasis by constructing a tumor acidosis model AFeNPs@CAI. AFeNPs@CAI nanocomposites were composed of unique amorphous iron nanoparticles (AFeNPs) loaded with CAI, which facilitated the Fenton reaction and enlarged the oxidative damage to cells. At the same time, the over-expression of CAIX in cancer cells was inhibited by CAI, and the possibility of tumor invasion and metastasis was effectively inhibited by re-established tumor acidosis. The decrease of pH$_i$ effectively increased productivity of ·OH by the Fenton reaction based on AFeNPs, and aggravated the oxidative stress in tumor cells and induced cells apoptosis. Thus, CAI not only potentiates the application of CDT in tumor therapy, but also provides a new anticancer idea of re-establishing TME for a better therapeutic effect, showing promising effective treatment of tumors.

In addition, research group of Angeli evaluated a series of telluride-containing compounds bearing the benzenesulfonylamide group in vitro and found they could act as an effective inhibitor of carbonic anhydrase IX. These compounds exhibited inhibitory activity against tumor-associated CA IX at low concentrations (KI 2.2–2.9 nM), providing the possibility of treating the MDA-MB-231 breast cancer. In this case, the organotellurium derivatives as CAI inhibitors have opened up new avenues for novel antitumor agents.

Furthermore, it was found that the loss of CAIX expression in 4T1 mouse metastatic breast cancer cells mediated by shRNA led to the regression in orthotopic mammary tumors and inhibited spontaneous lung metastasis. Meanwhile, the stable depletion of CAIX in MDA-MB-231 human breast cancer xenografts also resulted in the weakening of primary tumor growth. What’s more, a novel CAIX-specific small molecule inhibitor was used to treat CAIX-positive 4T1 breast tumors in mice. The inhibitor mimicked the effect of CAIX deficiency in vitro and significantly inhibited the tumor growth and metastasis in both spontaneous and experimental metastasis models but had no inhibitory effect on CAIX-negative tumors. The similar inhibitory effects were observed on primary tumor growth in orthotopic tumor mice bearing
Table 1 The Inhibitors for Proton Pumps

| Proton Pumps | Inhibitors | Inhibition Model | Ref. |
|--------------|------------|------------------|------|
| CAIX         | Sulfonamide/sulfamate | Breast tumor cell lines | [67] |
| U-140 [sulfonamide] | 4T1 tumor /MDA-MB-231 | [68] |
| FC9-398A [ureidosulfamates] | TNBC | [69] |
| Glycosyl coumarin | HT-29 cells | [70] |
| Indanesulfonamide | HT-29 colorectal carcinoma cells | [71] |
| siRNA | 4T1 breast tumors | [72] |
| siRNA | BT-549 cell | [73] |
| Telluride containing compounds bearing the benzene sulfonamide | MDA-MB-231 cell | [74] |
| Sulfonamide dicarbaboranes | - | [75] |
| Saccharide-modified thiazole sulfonamide derivatives | MDA-MB-231 cell | [76] |
| OCT [octyl disulfamate] | HCT-116 | [77] |
| 2H-benzo [e] [1,2,4] thiadiazin-3(4H)-one-1,1-dioxides (BTD) | MDA-MB-231 cell | [78] |
| SLC-149[4-(3-(2,4-difluorophenyl)-oxoimidazolidin-1-y1) benzene sulfonamide] | MDA-MB-231 cell | [79] |
| Sulfonamide dicarbaboranes | - | [80] |
| OCT [octyl disulfamate] | 4T1 breast tumor cells | [81] |
| SLC-149[4-(3-(2,4-difluorophenyl)-oxoimidazolidin-1-y1) benzene sulfonamide] | PC3 tumor | [82] |
| 2H-benzo [e] [1,2,4] thiadiazin-3(4H)-one-1,1-dioxides (BTD) | MDA-MB-231 xenograft tumor | [83] |
| SLC-149[4-(3-(2,4-difluorophenyl)-oxoimidazolidin-1-y1) benzene sulfonamide] | Melanoma | [84] |
| 2,4-dihydro-1,2,4-triazole-3-thione derivative 9c | - | [85] |
| 2-Methoxy-4-N, N-dialkyl cyanocinnamic acids | Myeloma | [86] |
| 2-Hydroxy-4-N, N-dialkyl cyanocinnamic acids | Human lymphoma and colon carcinoma cells | [87] |
| 2-Hydroxy-4-N, N-dialkyl cyanocinnamic acids | 4T1 breast tumor cells | [88] |
| 2-Hydroxy-4-N, N-dialkyl cyanocinnamic acids | PC3 tumor | [89] |
| 2-Hydroxy-4-N, N-dialkyl cyanocinnamic acids | MDA-MB-231 xenograft tumor | [90] |
| 2-Hydroxy-4-N, N-dialkyl cyanocinnamic acids | Melanoma | [91] |
| 2-Hydroxy-4-N, N-dialkyl cyanocinnamic acids | - | [92] |
| MCT | MCT1 | α-cyano-4-hydroxycinnamate (CHC) | [93] |
| MCT1/2 | AR-C155858 | AZD3965 | [94] |
| MCT4 | siRNA | AZD3965 | [95] |
| | 2-Methoxy-4-N, N-dialkyl cyanocinnamic acids | - | [96] |
| | Diclofenac | MCF-7 cell | [97] |
| | [F-18] FACH | MCF-7 spheroids | [98] |
| NHE | Anti NHE1 siRNA | Hepatocellular carcinoma | [99] |
| | Amiloride | SMMC-7721 cell | [100] |
| | 5-(N-ethyl-N-isopropyl) amiloride | HepG2 cells | [101] |
| | Cariporide | MDA-MB-231 | [102] |
| | Cariporide [HOE-642] | Mouse glioms | [103] |
| | siRNA | Mouse glioms | [104] |
| | KR-33028 [4-cyano (benzo[b]thiophene-2-carbonyl) guanidine] | Triple-negative breast cancer | [105] |
| | HMA [5- (N, N-hexamethylene)-amiloride] | MCF-7 spheroids | [106] |
| | DMA [5- (N, N-Dimethyl) amiloride] | MCF-7 spheroids | [107] |
| | Zoniporide | Fibroblasts | [108] |
| | Sabiporide | Vascular smooth muscle cell | [109] |
| | DEPC (diethyl pyrocarbonate) | Fibroblasts | [110] |
| | KR-32570[5-(2-methoxy-5-chloro-5-phenyl) furan-2-yl-carbonyl] guanidine | H9C2 cells | [111] |
| | T-162559 | CHO-K1 cells | [112] |
| | SL-59.1227[imidazolypiperidine] | Hamster fibroblast cell lines | [113] |
| | EIPA [5-(N-ethyl-N-isopropyl) amiloride] | Human myeloid K562 cells | [114] |
| | DEPC (diethyl pyrocarbonate) | Fibroblasts | [115] |
| | Zoniporide | Vascular smooth muscle cell | [116] |
| | Sabiporide | Fibroblasts | [117] |
| | DEPC (diethyl pyrocarbonate) | H9C2 cells | [118] |
| | KR-33028 [4-cyano (benzo[b]thiophene-2-carbonyl) guanidine] | CHO-K1 cells | [119] |
| | HMA [5- (N, N-hexamethylene)-amiloride] | MCF-7 spheroids | [120] |
| | DMA [5- (N, N-Dimethyl) amiloride] | MCF-7 spheroids | [121] |

**Note:** Table 1 provides a list of inhibitors and their corresponding inhibition models for various proton pumps. The table includes references for each entry, indicating the source of the data or study that documented the inhibition. The inhibitors listed are intended to modulate the activity of these pumps in specific cell lines or conditions, as indicated by the reference numbers linked to each entry.
lung metastatic MDA-MB-231 LM2-4Luc cells. Therefore, targeting CAIX activity with specific drug inhibitors may help inhibit disease progression.

Some carbonic anhydrase-related proteins also affect the expression of carbonic anhydrase. Cullin-associated NEDD8-dissociation protein 1 (CAND1), a nuclear protein involved in gene transcription and SCF ubiquitin ligase complex assembly, which could interact with CAIX. In fact, this interaction was identified, and the low levels of CA IX were observed in cells with reduced CAND1 expression through shRNA-mediated interference. Due to the role of CAND1 in stabilizing CAIX, these molecules might have potent to reduce the amount of CAIX in hypoxic cancer cells. It might be a new prospect for the design of anticancer drugs targeting CAIX.

In summary, the combination of CAI and CDT can significantly amplify the oxidative stress in tumor sites, effectively kill the tumor, as well as reduce its side effects on the normal tissues.

Monocarboxylate Transporters (MCT)

The Monocarboxylate transporters (MCTs), are a family of 14 members and products of the SLC16 gene family, among which MCT1–4 can transport one monocarboxylic acid molecule across the cell membrane such as L-lactate and pyruvate and so on. Different from other MCTs, MCT4 is activated by HIF-1α and will exhibit 3–5 fold mRNA expression during hypoxia, showing significantly higher tissue expression in hypoxic region of tumor site. MCT-4 is also a low-affinity and high-capacity lactate transporter, which exists in cells with increased glycolytic activity and participates in the release of lactate in cell glycolysis. MCT4 is highly expressed in various types of solid tumors, for instance, the breast cancer. Previous studies showed that the cells expressing MCT-4 showed stronger invasion behavior than those without MCT-4 expression. Therefore, silencing MCT-4 gene and using MCT4 inhibitors are expected to reduce pH and improve the efficiency of CDT.

An innovative amorphous iron oxide (AIO) RNAi NP platform was constructed by research group of Liu. RNAi NP platform could regulate the glycolysis pathway by silencing MCT-4 to block the outflow of intracellular lactate/H⁺, optimizing the catalytic efficiency of Fenton/Fenton-like reactions and upgrading the therapeutic performance of CDT. It was worth noting that blocking intracellular lactate efflux by MCT-4 silencing also could further stimulate more H₂O₂ production to amplify the Fenton-like reaction and oxidative damage to tumor cells, and result in the effective combination therapy (Figure 7). In short, MCT-4 inhibitors are of great significance for the upregulation of total ROS by CDT, which ultimately improves the anti-cancer efficiency of CDT.
**Na⁺/H⁺ Exchanger (NHE1)**

NHE1, an H⁺-regulated membranous transport protein, is encoded by human solute carrier family 9A1 (SLC9A1) gene and can maintain an acidic extracellular pH in cancer cells.⁶⁵,⁹⁴ NHE1 drives H⁺ efflux to exchange Na⁺ influx to maintain pHi, which is an important driving force for glycolytic metabolism.¹²⁴ The transmembrane domain of NHE1 is necessary for ion transport, and its ~300-residue long, regulatory C-terminal cytosolic tail controls the pHi set point of the transporter and is also required for allosteric NHE1 regulation.¹²⁵ So far, 10 isoforms have been identified in the human NHE family.¹²⁶ In addition, the hypoxic and serum-depleted tumor microenvironment further promote excessive activation of NHE1.¹²⁷ Researches show that the activation of NHE1 enhances the migratory capability and invasiveness of human melanoma cells and breast carcinoma cells.¹²⁸ Thus, it is important for inhibiting H⁺ efflux by choosing a specific NHE1 inhibitor.

NHE1 inhibitors partially inhibit NHE1 by competing with Na⁺ at the transport site.¹²⁹ At present, NHE1 inhibitor has not yet been combined with CDT, but their advantages in tumor treatment have been proved. The stable shRNA-mediated NHE1 gene knockdown (KD) in the MDA-MB-231 triple-negative breast cancer (TNBC) cell line significantly lowered pH(i) and capacity for pH(i) recovery after an acid load.¹³⁰ KR-33028 (4-cyano (benzo[b]thiophene-2-carbonyl) guanidine), an effective and selective NHE1 inhibitor, could inhibit metastatic of TNBC cells and reduce cell invasion through the extracellular matrix. Meanwhile, the effect of KR-33028 on MDA-MB-231 cells lacking NHE1 expression (231koNHE1) was also evaluated. It was found that there was no difference between untreated control cells and 231koNHE1 cells treated with KR-33028. Thus, KR-33028-mediated inhibition of NHE1 has implications for limiting cell metastasis in vivo.⁹⁶

The three-dimensional (3D) spheroids with MDA-MB-231 and MCF-7 cell were constructed and treated with pyrazinoylguanidine-type NHE1 inhibitors for 2–7 days, followed by analyses of the viability and death-associated signaling. It was found that this type of NHE1 inhibitor could reduce the viability of breast cancer spheres in a dose-dependent manner.⁹⁷ In conclusion, the introduction of NHE1 inhibitor in the nanoparticle is helpful to prevent H⁺ efflux and effectively prevents the invasion of the TNBC. Therefore, by inhibiting NHE1 activity not only contributes to CDT optimization, but also provides an opportunity to develop more specific approaches to regulate pH of the TME.

**Na⁺-HCO₃⁻ Cotransporter NBCn1**

Na⁺-HCO₃⁻ cotransporter NBCn1 constitutes the majority of the acid extrusion capacity in human breast carcinomas.¹₃¹ Most evidence indicates that the protein expression of cotransporter NBCn1 is increased in primary breast carcinomas.
and lymph node metastases. Compared to the matched normal breast tissue, the expression of NBCn1 protein in human breast cancer is about twofold to threefold of that in normal one. Driven by the Na\(^+\) concentration gradient, NBCn1 normally can move Na\(^+\) and HCO\(_3^-\) into cells. The upregulated cellular net acid extrusion in breast cancer depends on NBCn1-mediated HCO\(_3^-\) uptake. However, Na\(^+\)-HCO\(_3^-\) cotransporter NBCn1 inhibitor can block HCO\(_3^-\) uptake and its transformation to carbon dioxide driven by CAIX, and finally inhibiting H\(^+\) emission, maintaining pH values in cell, and thereby limiting cell proliferation and breast cancer occurrence. Thus, NBCn1 is widely expressed and likely to play an important physiological role in pH regulation in numerous tumors.

The functional consequences of NBCn1 knockout (KO) were tested during the breast cancer development. The results showed that NBCn1 gene mutation delayed the development of breast cancer. Compared with wild-type (WT) mice, the tumor growth rate was about 65% decreased in NBCn1 KO mice, while the incubation period of breast tumors was prolonged. The cell proliferation rate of NBCn1KO cancer mice was about 60% lower than that of WT by Ki-67 and phosphohistone H-3 staining. It was also found that CO\(_2\), HCO\(_3^-\) dependent net acid extrusion was suppressed and the steady-state pH decreased in breast cancer tissue of NBCn1 KO mice. The disruption of NBCn1 expression also delayed the growth of the ErbB2-induced breast carcinogenesis. Take the survival period for example, it was about 9.5 months for a median tumor-free in wild-type mice, but prolonged to 12 months in NBCn1-knockout mice. Thus, these findings demonstrated that NBCn1 might act as a target for anti-cancer therapy, even combined with CDT to improve the efficiency of cancer treatment.

### Conclusion

Compared with traditional cancer therapy, CDT is a new cancer treatment method. Because of its high specificity and sensitivity, researchers have paid extensive attention to converting H\(_2\)O\(_2\) into highly toxic ·OH by initiating Fenton and Fenton-like reactions. Although the TME is weakly acidic, its pH value is unsuitable for Fenton reaction occurrence. In order to overcome the limitation, strategies to improve CDT efficiency in view of acidification is summarized in this review. Increasing the concentration of H\(^+\) in tumor cells is the first way to be studied. For example, by introducing the catalytic enzymes and exogenous acids, such as GOx, AAO, PA, is able to reduce the pH value in tumors and improve the efficiency of CDT against cancer. The mitochondrial complex I inhibitor is used to block the oxidative phosphorylation of cell respiration, resulting in forcing cells to produce lactic acid by anaerobic glycolysis and increasing the intracellular acidity. Similarly, the proton pump protein inhibitors, such as CA IX, MCT-4, NHE1, NBCn1, are introduced to inhibit intracellular lactate/H\(^+\) efflux and reduce intracellular pH. These catalytic enzymes and inhibitors will serve as potential cancer adjuvants for CDT. Except for NBCn1, other proton pumps are mainly activated under anoxic conditions. Therefore, we can also inhibit the function of proton pump from the perspective of increasing tumor oxygen concentration, so as to improve the acidity of TME and the efficiency of CDT.

Many research works have proved that acidification of TME does have effect in promoting the action of CDT, but there are still some challenges. For GOx, it is critical to ensure that its internal substance, GOx, is not released before reaching the tumor site. GOx catalysis can consume glucose and O\(_2\), which will damage the normal cells if the leakage occurs during transportation. Therefore, a variety of fine therapeutic nanocarriers were developed, including cell membrane (CM), metal polyphenol networks, metal-organic frameworks, zeolitic imidazolate framework. All of these nanocarriers were confirmed to maximize its safety and improve the therapeutic effects and reduce side effects.

In addition, acidification can combine with other factors to affect Fenton reaction. Firstly, by strengthening the conversion rate of Fe\(^3+\) to Fe\(^2+\), the Fe\(^{3+}\) local electron density can be adjusted to increase the electron density. At this time, electrons will move the atoms from the non-reaction center to the reaction area and the reaction dynamic process is accelerated. Secondly, regulating the TME to enhance CDT performance, such as increasing H\(_2\)O\(_2\) concentration in tumor, and reducing the excessive intracellular antioxidant GSH, can improve efficiency of CDT. In addition, CDT-based combination therapy can be developed, such as CDT-PDT, CDT-PTT, CDT-chemotherapy, CDT-immunotherapy, CDT-RT, CDT-SDT, CDT-starvation therapy, which can produce significant synergistic effects and reduce the side effects of CDT agents. However, in order to address the current barriers of CDT for clinical applications, we should try to avoid large doses, complex synthesis processes and cumbersome auxiliary devices when
It is important to develop a simple and efficient CDT nanoplatform for the field of cancer nanomedicine. At present, different from the classic pH-dependent Fenton/Fenton-like reaction, some researchers have developed a pH-independent reaction to increasing the production of ·OH, which is also confirmed the certain potential in CDT treatment, but its mechanism is still needed to be explored. In summary, CDT shows a broad application prospect in cancer treatment and is worth further exploration in different tumors. The acidic TME is crucial for Fenton and Fenton-like reactions and plays a decisive role in the anti-tumor effect of CDT. So, it is the unremitting goal to design nano-platforms with simpleness, good biocompatibility, low toxic, and high efficiency to CDT, as well as the perspective therapy to achieve early clinical application.

Acknowledgments
We acknowledge funding support by Key Research and Development Program of Shaanxi (Program No. 2021SF-106), the Innovation Capability Support Program of Shaanxi (Program No.2020TD-042), the joint funding from Department of Science and Technology of Shaanxi Province and Northwestern Polytechnical University (No. 2020GXLH-Z-021) and the innovation foundation for doctor dissertation of Northwestern Polytechnical University (No. CX2021099).

Disclosure
The authors report no conflicts of interest in this work.

References
1. Jia CY, Guo YX, Wu FG. Chemodynamic therapy via fenton and fenton-like nanomaterials: strategies and recent advances. Small. 2022;18 (6):2103868. doi:10.1002/smll.202103868
2. Bai Y, Zhao J, Zhang L, et al. A smart near-infrared carbon dot-metal organic framework assembles for tumor microenvironment-activated imaging and chemodynamic-photothermal combined therapy. Adv Healthcare Mater. 2022. e2102759–e2102759. doi:10.1002/adhm.202102759
3. Gao FL, Wu J, Gao HQ, et al. Hypoxia-tropic nanozymes as oxygen generators for tumor-favoring theranostics. Biomaterials. 2020;230:119635. doi:10.1016/j.biomaterials.2019.119635
4. Zhang SC, Cao CY, Lv XY, et al. A H2O2 self-sufficient nanoplatform with domino effects for thermal-responsive enhanced chemodynamic therapy. Chem. Sci. 2020;11(7):1926–1934. doi:10.1039/C9SC05506A
5. Li Y, Jia R, Lin HM, Sun XL, Qu FY. Synthesis of MoSe2/CoSe2 nanosheets for NIR-enhanced chemodynamic therapy via synergistic in-situ H2O2 production and activation. Appl Organomet Chem. 2020;31(8):2008420.
6. Lin J, He T, Yuan Y, et al. Light-activated transformable ferrous ion delivery system for photothermal primed chemodynamic therapy. Angewandte Chemie. 2020;60(11):6047–6054.
7. Jia T, Wang Z, Sun QQ, et al. Intelligent Fe-Mn layered double hydroxides nanosheets anchored with upconversion nanoparticles for oxygen-elevated synergetic therapy and bioimaging. Small. 2020;16(46):2001343. doi:10.1002/smll.202001343
8. Nie X, Xia L, Wang HL, et al. Photothermal therapy nanomaterials boosting transformation of Fe(III) into Fe(II) in tumor cells for highly improving chemodynamic therapy. ACS Appl Mater Inter. 2019;11(35):31735–31742. doi:10.1021/acsami.9b11291
9. He Z, Zhang H, Li H, et al. Preparation, biosafety, and cytotoxicity studies of a newly tumor-microenvironment-responsive biodegradable mesoporous silica nanosystem based on multimodal and synergistic treatment. Oxid Med Cell Longev. 2020;2020:7152173. doi:10.1155/2020/7152173
10. Li SS, Huang J, Guo Y, et al. PAC1 receptor mediates electroacupuncture-induced neuro and immune protection during cisplatin chemotherapy. Front Immunol. 2021;12:714244. doi:10.3389/fimmu.2021.714244
11. Zheng NN, Wang Q, Li CL, et al. Responsive degradable theranostic agents enable controlled selenium delivery to enhance photothermal radiotherapy and reduce side effects. Adv Healthc Mater. 2020;10(10):2002024. doi:10.1002/adhm.202002024
12. Tang ZM, Liu YY, He MY, Bu WB. Chemodynamic therapy: tumor microenvironment-mediated fenton and fenton-like reactions. Angewandte Chemie. 2019;58(4):946–956. doi:10.1002/anie.201805664
13. Zhang HW, Lu F, Pan W, et al. A dual-catalytic nanoreactor for synergistic chemodynamic-starvation therapy toward tumor metastasis suppression. Biomater Sci-Uk. 2021;9(10):3814–3820. doi:10.1039/D1BM00240F
14. He YL, Jin XY, Guo SW, Zhao HX, Liu Y, Ju HX. Conjugated polymer-ferrocence nanoparticle as an NIR-II light powered nanoamplifier to enhance chemodynamic therapy. ACS Appl Mater Inter. 2021;13(27):31452–31461. doi:10.1021/acsami.1c06613
15. Hu CL, Wang JZ, Liu SN, et al. Urchin-shaped metal organic/hydrogen-bonded framework nanocomposite as a multifunctional nanoreactor for catalysis-enhanced synergistic therapy. ACS Appl Mater Inter. 2021;13(4):4825–4834. doi:10.1021/acsami.0c019584
16. Fu LH, Wan YL, Qi C, et al. Nanocatalytic theranostics with glutathione depletion and enhanced reactive oxygen species generation for efficient cancer therapy. Adv Mater. 2021;33(7):2006892. doi:10.1002/adma.202006892
17. He H, Yang QY, Li HM, et al. Hollow mesoporous MnO2-carbon nanodot-based nanoplatform for GSH depletion enhanced chemodynamic therapy, chemotherapy, and normal/cancer cell differentiation. Microchim Acta. 2021;188(4):141. doi:10.1007/s00604-021-04801-5
18. Yang GB, Ji JS, Liu Z. Multifunctional MnO2 nanoparticles for tumor microenvironment modulation and cancer therapy. Wires Nanomed Nanobi. 2021;13(6):1720. doi:10.1002/wnan.1720
Chen et al

19. Bao YW, Hua XW, Zeng J, Wu FG. Bacterial template synthesis of multifunctional nanospindles for glutathione detection and enhanced cancer-specific chemo-chemodynamic therapy. Research-China. 2020;2020:9301215.

20. Kang YW, Hwang KY. Effects of reaction conditions on the oxidation efficiency in the Fenton process. Water Res. 2000;34(10):2786–2790. doi:10.1016/S0043-1354(99)00388-7

21. Ke WD, Li JJ, Mohammed F, et al. Therapeutic polymersome nanoreactors with tumor-specific activable cascade reactions for cooperative cancer therapy. Adv. Mater. 2019;31(2):2357–2369. doi:10.1002/adma.201910085

22. Dong SM, Dong YS, Jia T, et al. GSH-depleted nanozymes with hyperthermia-enhanced dual enzyme-mimic activities for tumor nanocatalytic therapy. Adv. Mater. 2020;32(42):2002439. doi:10.1002/adma.202002439

23. Zhang Y, Eltabey O, Meng YT, et al. Tumor microenvironment-responsive mesoporous silica nanoparticles for dual delivery of doxorubicin and chemodynamic therapy (CDT) agent. New J. Chem. 2020;44(6):2578–2586. doi:10.1039/C9NJ05427H

24. Tang W, Gao HB, Ni DL, et al. Bovine serum albumin-templated nanoplatform for magnetic resonance imaging-guided chemodynamic therapy. J. Nanobiotechnol. 2019;17:68. doi:10.1186/s12951-019-0501-3

25. Yang SD, Wang Y, Ren ZX, Chen MT, Chen WL, Zhang XN. Stepwise pH/reduction-responsive polymeric conjugates for enhanced drug delivery to tumor. Mat Sci Eng C-Mater. 2018;82:234–243. doi:10.1016/j.msec.2017.08.079

26. Li JJ, Kataoka K. Chemo-physical strategies to advance the in vivo functionality of targeted nanomedicine: the next generation. J. Am. Chem. Soc. 2021;143(2):538–559. doi:10.1021/jacs.0c09029

27. Zhou H, Li XW, Niu DC, et al. Ultrasensitive chemodynamic therapy: bimetallic peroxide triggers high pH-activated, synergistic effect/\(\text{H}_2\text{O}_2\) self-supply-mediated cascade fenton chemistry. Adv. Healthc. Mater. 2021;10(9):2002126. doi:10.1002/adhm.202020126

28. Naser FJ, Jackstadt MM, Fowlie-Grider R, et al. Isotope tracing in adult zebrafish reveals alanine cycling between melanoma and liver. Cell Metab. 2021;33(7):1497–1499. doi:10.1016/j.cmet.2021.04.014

29. Butler M, van der Meer LT, Van Leeuwen FN. Amino acid depletion therapies: starving cancer cells to death. Trends Endocrin Met. 2021;32(6):367–381. doi:10.1016/j.tem.2021.03.003

30. Yang C, Gao M, Zhao H, et al. A dual-functional biomimetic-mineralized nanoplatform for glucose detection and therapy with cancer cells in vitro. J. Mater Chem B. 2021;9(18):3885–3891. doi:10.1039/D1TB00324K

31. Ming J, Zhu TB, Yang WH, et al. \(\text{Pd@Pt-GOx@HA}\) as a novel enzymatic cascade nanoreactor for high efficiency-starching enhanced chemodynamic cancer therapy. ACS Appl Mater Inter. 2020;12(46):51249–51262. doi:10.1021/acsami.0c15121

32. Deng FA, Fan GL, Yuan P, et al. A self-accelerated biocatalyst for glucose-initiated tumor starvation and chemodynamic therapy. Chem Commun. 2020;56(93):14633–14636. doi:10.1039/D0CC06483A

33. Yang GB, Wang DD, Phua SZF, et al. Albumin-based therapeutics capable of glutathione consumption and hydrogen peroxide generation for synergic chemodynamic and chemotherapy of cancer. Adv. Mater. 2022;34(2):2319–2329. doi:10.1002/adma.202100856

34. Wang M, Wang DM, Chen Q, Li CX, Li ZQ, Lin J. Recent advances in glucose-oxidase-based nanoaterials for tumor therapy. Small. 2019;15(51):1903895. doi:10.1002/smll.201903895

35. Wang Q, Niu DG, Shi JS, Wang LL. A three-in-one ZIFs-derived \(\text{CuCoO@GOx@PCNs}\) hybrid cascade nanzyme for immunotherapy/enhanced starvation/photothermal therapy.ACS Appl Mater Inter. 2021;13(10):11683–11695. doi:10.1021/acsami.1c01006

36. Liu XP, Liu ZW, Dong K, et al. Tumor-activatable ultrasmall nanogenerator for enhanced penetration and deep catalytic therapy. Biomaterials. 2020;258:120265. doi:10.1016/j.biomaterials.2020.120263

37. Fang C, Deng Z, Cao GD, et al. Co-Ferrocene MOF/\(\text{Glucose oxidase}\) as cascade nanozyme for immunotherapy. Adv. Funct. Mater. 2020;30(16):2019085. doi:10.1002/adfm.2019085

38. Li JJ, Li YF, Wang YH, et al. Polymer prodrug-based nanoreactors activated by tumor acidity for orchestrated oxidation/chemodynamic therapy. Nano Lett. 2017;17(11):6983–6990. doi:10.1021/acs.nanolett.7b03551

39. Li JJ, Anraku Y, Kataoka K. Self-boosting catalytic nanoreactors integrated with triggerable crosslinking membrane networks for initiation of immunogenic cell death by pyroptosis. Angewandte Chemie. 2020;59(32):13526–13530. doi:10.1002/anie.202004180

40. Li JJ, Dirisala A, Ge ZS, et al. Therapeutic vesicular nanoreactors with tumor-specific activation and self-destruction for synergistic tumor ablation. Angewandte Chemie. 2017;56(45):14025–14030. doi:10.1002/anie.201706964

41. Yang X, Yang Y, Gao F, Wei JI, Qian CG, Sun MJ. Biomimetic hybrid nanozymes with self-supplied \(\text{H}^+\) and accelerated \(\text{O}_2\) generation for enhanced starvation and photodynamic therapy against hypoxic tumors. Nano Lett. 2019;19(7):4334-4342. doi:10.1021/acs.nanolett.9b00934

42. Zhang L, Wang ZZ, Zhang Y, et al. Erythrocyte membrane cloaked metal-organic framework nanoparticle as biomimetic nanoreactor for starvation-activated colon cancer therapy. ACS Nano. 2018;12(10):10201–10211. doi:10.1021/acsnano.8b05200

43. Shao YJ, Wang ZY, Hao YT, et al. Cascade catalytic nanoplatform based on “butterfly effect” for enhanced immunotherapy. Adv. Healthc. Mater. 2021;10(8):2002171. doi:10.1002/adhm.2020201271

44. Zhang YW, Hu HR, Liu WW, et al. Amino acids and \(\text{RagD}\) potentiate mTORC1 activation in CD8(+) T cells to confer antitumor immunity. J. Immunother Cancer. 2021;9(4):e002137. doi:10.1136/jitc-2020-002137

45. Mazzoni A, Capone M, Ramazzotti M, et al. IL4I1 is expressed by head-neck cancer-derived mesenchymal stromal cells and contributes to suppress T cell proliferation. J. Clin. Med. 2021;10(2):2111. doi:10.3390/jcm102111

46. Cormerais Y, Vucetic M, Pouyssegur J. Targeting amino acids transporters (SLC's) to starve cancer cells to death. Biochem Biophys Res Co. 2019;520(4):691–693. doi:10.1016/j.bbrc.2019.10.173

47. Zhang L, Wu WT. Isolation and characterization of ACTX-6: a cytotoxic \(\text{L-amino acid}\) oxidase from Agkistrodon acutus snake venom. Nat Prod Res. 2008;22(6):554–563. doi:10.1080/14786410701592679

48. Chu Q, Zhu H, Liu B, et al. Delivery of amino acid oxidase via catalytic nanocapsules to enable effective tumor inhibition. J. Mater Chem B. 2020;8(38):5846–5857. doi:10.1039/D0TB01425G

49. Sanborn CD, Chacko JV, Digman M, Ardo S. Interfacial and nanoconfined effects decrease the excited-state acidity of polymer-bound photocatalysts. Chem.-Us. 2019;5(6):1648–1670. doi:10.1021/acs.chempr.0c00422

50. Peretz-Soroka H, Pevzner A, Davidi G, et al. Manipulating and monitoring on-surface biological reactions by light-triggered local pH alterations. Nano Lett. 2015;15(7):4758–4768. doi:10.1021/nl501578

51. Liao Y. Design and applications of metastable-state photoacids. Accounts Chem. Res. 2017;50(8):1956–1964.
52. Yan DM, Chen JR, Xiao WJ. New roles for photoexcited Eosin Y in photochemical reactions. Angewandte Chemie. 2019;58(2):378–380. doi:10.1002/anie.201811102

53. Chen X, Chen Y, Wang C, et al. NIR-triggered intracellular H+ transients for lamellipodia-collapsed antimetastasis and enhanced chemodynamic therapy. Angew Chem Int Ed Engl. 2021;60(40):21905–21910. doi:10.1002/anie.202107588

54. McKenzie M, Liolitsa D, Akinshina N, et al. Mitochondrial NDS gene variation associated with encephalomyopathy and mitochondrial ATP consumption. J Biol Chem. 2007;282(51):36845–36852. doi:10.1074/jbc.M704158200

55. Park JS, Sharma LK, Li HZ, et al. A heteroplasmic, not homoplasmic, mitochondrial DNA mutation promotes tumorigenesis via alteration in reactive oxygen species generation and apoptosis. Hum Mol Genet. 2009;18(9):1578–1589. doi:10.1093/hmg/ddp069

56. Chen Z, Wei XY, Wang XY, et al. NDUF4L2 promotes glioblastoma progression, is associated with poor survival, and can be effectively targeted by apatinib. Cell Death Dis. 2021;12(4):377. doi:10.1038/s41419-021-03646-3

57. Chaube B, Malvi P, Singh SV, Mohammad N, Meena AS, Bhat MK. Targeting metabolic flexibility by simultaneously inhibiting respiratory complex I and lactate generation retards melanoma progression. Oncotarget. 2015;6(35):37281–37299. doi:10.18632/oncotarget.6134

58. Heinz S, Freyberger A, Lawrenz B, Schladt L, Schmuck G, Ellinger-Ziegelbauer H. Mechanistic investigations of the mitochondrial complex i inhibitor rotenone in the context of pharmacological and safety evaluation. Sci Rep-Ukr. 2017;7:45465. doi:10.1038/srep45465

59. Shi LN, Wang YJ, Zhang C, et al. An acidity-unlocked magnetic nanoplatorm enables self-boosting ROS generation through upregulation of lactate for imaging-guided highly specific chemodynamic therapy. Angewandte Chemie. 2021;60(17):9562–9572. doi:10.1002/anie.202014415

60. Ju R, Guo L, Li J, et al. Carboxyamidotriazole inhibits oxidative phosphorylation in cancer cells and exerts synergistic anti-cancer effect with glycolysis inhibition. Cancer Lett. 2016;370(2):232–241. doi:10.1016/j.canlet.2015.10.025

61. Cornelissen J, Linders RJA, Vangennip AH, Vandenbogert C, Voute PA, Vankulenburg ABP. Metiodobenzylguanidine inhibits Complex-I and complex-III of the respiratory-chain in the human cell-line Molt-4. Biochim Pharmacol. 1995;49(4):471–477. doi:10.1016/0006-2025/94/00450-Z

62. Tian H, Zhang M, Jin G, Jiang Y, Luan Y. Cu-MOF chemodynamic nanopllatform via modulating glutathione and H2O2 in tumor microenvironment for amplified cancer therapy. J Colloid Interface Sci. 2021;587:358–366. doi:10.1016/j.jcis.2020.12.028

63. Xu P, Zhang Y, Ge F, Zhang F, He X, Gao X. Modulation of tumor microenvironment to enhance radiotherapy efficacy in esophageal squamous cell carcinoma by inhibiting carboanhydrate IX. Front Oncol. 2021;11:637252. doi:10.3389/fonc.2021.637252

64. Papakonstantinou E, Vlachakis D, Thireou T, Vlachoyiannopoulos PG, Eliopoulos E. A holistic evolutionary and 3D pharmacophore modelling study provides insights into the metabolism, function, and substrate selectivity of the human monocarboxylate transporter 4 (hMCT4). Int J Mol Sci. 2021;22(6):2918. doi:10.3390/ijms22062918

65. Hou KY, Liu J, Du YJ, et al. Dihydroartemisinin prompts amplification of photodynamic therapy-induced reactive oxygen species to exhaust Na/H exchanger 1-mediated glioma cells invasion and migration. J Photoch Photobio B. 2021;219:112192. doi:10.1016/j.jphotobiol.2021.12192

66. Toft NJ, Axelsen TV, Pedersen HL, et al. Acid-base transporters and pH dynamics in human breast carcinomas predict proliferative activity, metastasis, and survival. Elife. 2021;10:e84447. doi:10.7554/eLife.84447

67. Bozdag M, Ferrarini M, Ward C, et al. Carbonic anhydrase inhibitors based on sorafenib scaffold: design, synthesis, crystallographic investigation and effects on primary breast cancer cells. Eur J Med Chem. 2019;182:111600. doi:10.1016/j.ejmech.2019.111600

68. Lou Y, McDonald PC, Olomu A, Chia S, Ostlund C, Ahmad A. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carboxyl anhydrase IX inhibitors. Cancer Res. 2011;71(13):4733.

69. Williams KJ, Gieling RG. Preclinical evaluation of ureidosulfamate carboxy anhydrase IX/XII inhibitors in the treatment of cancers. Int J Mol Sci. 2019;20:23. doi:10.3390/ijms200620037

70. Kurt BZ, Sonmez F, Ozturk D, Akdemir A, Angeli A, Supuran CT. Synthesis of coumarin-sulfonamide derivatives and determination of their inhibitory activity on human breast cancer cells. Eur J Med Chem. 2020;219:112192. doi:10.1016/j.ejmech.2018.11.064

71. Kugler M, Holub J, Brynda J, et al. The structural basis for the selectivity of sulfonamide dicarbaboranes toward cancer-associated carbonic anhydrase IX. J Enzym Inhib Med Chem. 2020;35(1):1800–1810. doi:10.1080/14756366.2020.1816996

72. Ni K, Lan G, Song Y, Hao Z, Lin W. Biometric nanoscale metal-organic framework harnesses hypoxia for effective cancer radiotherapy and immunotherapy. Chem Sci. 2020;11(29):7641–7653. doi:10.1039/D0SC01949F

73. Lou Y, McDonald PC, Olomu A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 2011;71(9):3364–3376. doi:10.1158/0008-5472.CAN-10-4261

74. Samrella A, D’Avino G, Hill BS, et al. A novel inhibitor of carbonic anhydrases prevents hypoxia-induced TNBC cell plasticity. Int J Mol Sci. 2020;21(21):8405. doi:10.3390/ijms21218405

75. Angeli A, Pintea M, Maier SS, et al. Tellururides bearing benzensulfonamide as carboxy anhydrase inhibitors with potent antitumor activity. Bioorg Med Chem Lett. 2021;31:128147. doi:10.1016/j.bmcl.2021.128147

76. Kugler M, Holub J, Brynda J, et al. The structural basis for the selectivity of sulfonamide dicarbaboranes toward cancer-associated carboanhydrate IX. J Enzym Inhib Med Chem. 2020;35(1):1800–1810. doi:10.1080/14756366.2020.1816996

77. Zhang Z, Zhong Y, Han Z, et al. Synthesis, molecular docking analysis and biological evaluations of saccharide-modified thiadiazole carboxy anhydrase IX inhibitors. Eur J Med Chem. 2020;22(11). doi:10.1016/j.ejmech.2020.06.0277

78. D’Ascenzio M, Secci D, Carradori S, et al. 1,3-Dipolar Cycloaddition, HPLC enantioseparation, and docking studies of saccharin/isoxazole and saccharin/isoxazole derivatives as selective carboxyl anhydrase IX and XII inhibitors. J Med Chem. 2020;63(5):2470–2488. doi:10.1021/acs.jmedchem.9b01669

79. Malebari AM, Ibrahim TS, Salem IM, et al. The anticancer activity for the bumetanide-based analogs via targeting the tumor-associated membrane-bound human carboxy anhydrase-IX enzyme. Pharmaceuticals-Base. 2020;13(9):e34.
83. Hanson DJ, Nakamura S, Amachi R, et al. Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transport. Oncotarget. 2015;6(32):33568–33586. doi:10.18632/oncotarget.5598

84. Belouech-Babari M, Wantuch S, Galobart TC, et al. MCT1 inhibitor AZD3965 increases mitochondrial metabolism, facilitating combination therapy and noninvasive magnetic resonance spectroscopy. Cancer Res. 2017;77(21):5913–5924. doi:10.1158/0008-5472.CAN-16-2686

85. Guan X, Rodriguez-Cruz V, Morris ME. Cellular uptake of MCT1 inhibitors AR-C155858 and AZD3965 and their effects on MCT-mediated transport of l-lactate in murine 4T1 breast tumor cancer cells. Aps J. 2019;21(2):120.10do:1212248-018-0279-5

86. Liu YL, Xu XY, Tong WWL, et al. Engineering multifunctional RNAi nanomedicine to concurrently target cancer hallmarks for combinatorial therapy. Angewandte Chemie. 2018;57(6):1510–1513. doi:10.1002/anie.201710144

87. Puri S, Juvala K. Monocarboxylate transporter 1 and 4 inhibitors as potential therapeutics for treating solid tumours: a review with structure-activity relationship insights. Eur J Med Chem. 2020;45:199.

88. Renner K, Bruss C, Schnell A, et al. Restricting glycolysis preserves T cell effector functions and augments checkpoint therapy. Cell Rep. 2019;29(1):135. doi:10.1016/j.celrep.2019.08.068

89. Sadeghzadeh M, Moldovan RP, Teodoru R, Brust P, Wenzel B. One-step radiosynthesis of the MCTs imaging agent F-18 FACH by aliphatic F-18-labelling of a methylsulfonate precursor containing an unprotected carbonic acid group. Sci Rep-Uk. 2019:9:45.

90. Yang XK, Wang DS, Dong W, Song ZS, Dou KF. Expression and modulation of Na+/H+ exchanger 1 gene in hepatocellular carcinoma: a potential therapeutic target. J Gastroenterol Hepatol. 2011;26(2):364–370. doi:10.1111/j.1440-1746.2010.06382.x

91. Yang X, Wang D, Dong W, Song Z, Dou K. Suppression of Na+/H+ exchanger 1 by RNA interference or amiloride inhibits human hepatoma cell line SMMC-7721 cell invasion. Med Oncol. 2011;28(1):385–390. doi:10.1007/s12032-010-9447-x

92. Yang X, Wang D, Dong W, Song Z, Dou K. Inhibition of Na+/H+ exchanger 1 by 5-(N-ethyl-N-isopropyl) amiloride reduces hypoxia-induced hepatocarcinoma invasion and motility. Cancer Lett. 2010;295(2):198–204. doi:10.1016/j.canlet.2010.03.001

93. Wang J, Xu H, Wang Q, et al. CIAP1IN1 targets Na+/H+ exchanger 1 to mediate MDA-MB-231 cells’ metastasis through regulation of MMPs via ERK1/2 signaling pathway. Exp Cell Res. 2015;333(1):60–72. doi:10.1016/j.yexcr.2015.02.012

94. Sanyan XD, Luo LX, Begum G, et al. Elevated Na+/H+ exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas. J Exp Clin Cancer Res. 2018;37:456.

95. Zhu W, Carney KE, Piggot VM, et al. Glutamate-mediated microglial activation promotes glioma proliferation and migration: roles of Na+/H+ exchanger isoform 1. Carcinogenesis. 2016;37(9):839–851. doi:10.1093/carcin/bgw068

96. Amith SR, Wilkinson JM, Fliegel LR. Na+/H+ exchanger NHE1, suppresses metastatic potential of triple-negative breast cancer cells. Biochem Pharmacol. 2016;118:31–39. doi:10.1016/j.bcp.2016.08.010

97. Rolver MG, Elingaard-Larsen LO, Andersen AP, Counillon L, Pedersen SF. Pyrazine ring-based Na+/H+ exchanger specific NHE-1 inhibitor. Aacts J Chem. 2020;165(0):1–21.

98. Marala RB, Brown JA, Kong JX, et al. Pyrazine ring-based Na+/H+ exchanger specific NHE-1 inhibitor. Aacts J Chem. 2020;165(0):1–21.

99. Wu DM, Doods H, Stassen JM. Inhibition of human pulmonary artery smooth muscle cell proliferation and migration by zasiporide, a new specific NHE-1 inhibitor. J Pharmacol. 2002;451(1):37–41. doi:10.1002/jph.10093-3

100. Wu DM, Doods H, Stassen JM. Inhibition of human pulmonary artery smooth muscle cell proliferation and migration by zasiporide, a new specific NHE-1 inhibitor. J Pharmacol. 2002;451(1):37–41. doi:10.1002/jph.10093-3

101. Marala RB, Brown JA, Kong JX, et al. Pyrazine ring-based Na+/H+ exchanger specific NHE-1 inhibitor. Aacts J Chem. 2020;165(0):1–21.

102. Kawamoto T, Kimura H, Kusumoto K, et al. Potent and selective inhibition of the human Na+/H+ exchanger isoform 1. J Biochem. 2017;162(2):239–246. doi:10.1093/jb/mvx055

103. Lorrain J, Briand V, Favennec E, et al. Pharmacological profile of SL 59.1227, a novel inhibitor of the sodium/hydrogen exchanger. AAPS J. 2016;18:31–39. doi:10.1016/j.ajprenal.2013.02.012

104. Hansen DJ, Nakamura S, Amachi R, et al. Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transport. Oncotarget. 2015;6(32):33568–33586. doi:10.18632/oncotarget.5598

105. Nordstrom T, Andersson LC, Akerman KEO. Regulation of intracellular pH by electrogenic Na+/K+/H+ cotransporters in triple-negative breast cancer cell line SMMC-7721 cell invasion. Med Oncol. 2011;28(1):385–390. doi:10.1007/s12032-010-9447-x

106. Lee SP, Chao SC, Huang SF, Chen YL, Tsai YT, Loh SH. Expressional and functional characterization of intracellular pH regulators and effects of triple-negative breast cancer cells. Biochem Pharmacol. 2016;118:31–39. doi:10.1016/j.bcp.2016.08.010

107. Rolver MG, Elingaard-Larsen LO, Andersen AP, Counillon L, Pedersen SF. Pyrazine ring-based Na+/H+ exchanger specific NHE-1 inhibitor. Aacts J Chem. 2020;165(0):1–21.

108. Orlowski A, Vargas LA, Aiello EA, Alvarez BV. Elevated carbon dioxide upregulates NBCn1 Na+/H+ co-transporters in embryonic neural stem cell-derived radial glia-like cells. Biochem Pharmacol. 2019;16(1):1037–1048. doi:10.1016/j.bcp.2019.03.007

109. Radvak P, Repic M, Svastova E, et al. Suppression of carbonic anhydrase IX leads to aberrant focal adhesion and decreased invasion of tumor cells. Oncol Rep. 2013;29(3):1147–1153. doi:10.3892/or.2013.2226

110. Juhasz M, Chen J, Lendeckel U, et al. Expression of carbonic anhydrase IX in human pancreatic cancer. Aliment Pharm Ther. 2003;18(8):837–846. doi:10.1046/j.1365-2036.2003.01738.x

111. Stock C, Schwab A. Protons make tumor cells move like clockwork. Pflug Arch Eur J Phy. 2009;458(5):981–992. doi:10.1007/s00424-009-0677-8

112. Pastorek J, Pastorekova S, Callebaut I, et al. Cloning and characterization of Mn, a human tumor-associated protein with a domain homologous to carbonic-anhydrase and a putative helix-loop-helix DNA-binding segment. Oncogene. 1994;9(10):2877–2888.

113. Aldera AP, Govender D. Carbonic anhydrase IX: a regulator of pH and participant in carcinogenesis. J Clin Pathol. 2021;74(6):350–354. doi:10.1136/jclinpath-2020-207073

114. Zhang SY, Yang CM, Lu WQ, et al. A highly selective space-folded photo-induced electron transfer fluorescent probe for carbonic anhydrase isozymes I and its applications for biological imaging. Chem Commun. 2011;47(29):8301–8303. doi:10.1039/c1cc12386f
116. Chen XY, Zhang HL, Zhang M, et al. Amorphous Fe-based nanoagents for self-enhanced chemodynamic therapy by re-establishing tumor acidity. *Adv Funct Mater.* 2020;30(6):1908365. doi:10.1002/adfm.201908365

117. Buonanno M, Langella E, Zambrano N, et al. Disclosing the interaction of carbonic anhydrase IX with cullin-associated NEDD8-dissociated protein 1 by molecular modeling and integrated binding measurements. *ACS Chem Biol.* 2017;12(6):1460–1465. doi:10.1021/acschembio.7b00555

118. Chandel V, Maru S, Kumar A, et al. Role of monocarboxylate transporters in head and neck squamous cell carcinoma. *Life Sci.* 2021;279:119709. doi:10.1016/j.lfs.2021.119709

119. Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1 alpha-dependent mechanism. *J Biol Chem.* 2006;281(14):9030–9037. doi:10.1074/jbc.M511397200

120. Kiran D, Basaraba RJ. Lactate metabolism and signaling in tuberculosis and cancer: a comparative review. *Front Cell Infect Microbiol.* 2021;11:624607. doi:10.3389/fcimb.2021.624607

121. Luo F, Zou Z, Liu X, et al. Enhanced glycosylation, regulated by HIF-1alpha via MCT-4, promotes inflammation in arsenite-induced carcinogenesis. *Carcinogenesis.* 2017;38(6):615–626. doi:10.1093/carcin/bgx034

122. Hu X, Liu Z, Duan X, et al. Blocking MCT4 SUMOylation inhibits the growth of breast cancer cells. *Mol Carcinog.* 2021;60(10):702–714. doi:10.1002/mc.23336

123. Ruan Y, Zeng F, Cheng Z, Zhao X, Fu P, Chen H. High expression of monocarboxylate transporter 4 predicts poor prognosis in patients with lung adenocarcinoma. *Oncolett.* 2017;14(5):5727–5734. doi:10.3982/ol.2017.6964

124. Stock C, Pedersen SF. Roles of pH and the Na\(^{+}\)/H\(^{+}\) exchanger NHE1 in cancer: from cell biology and animal models to an emerging translational perspective? *Semin Cancer Biol.* 2017;43:5–16. doi:10.1016/j.semcancer.2016.12.001

125. Hendus-Altenuenger R, Vogensen J, Pedersen ES, et al. The intracellular lipid-binding domain of human Na\(^{+}\)/H\(^{+}\) exchanger 1 forms a lipid-protein co-structure essential for activity. *Commun Biol.* 2020;3(1):731. doi:10.1038/s42003-020-01455-6

126. Aiyoshi Y, Shiozaki A, Ichikawa D, et al. Na\(^{+}\)/H\(^{+}\) exchanger 1 has tumor suppressive activity and prognostic value in esophageal squamous cell carcinoma. *Oncotarget.* 2017;8(22):2209–2223. doi:10.18632/oncotarget.13645

127. Reshkin SJ, Cardone RA, Harguindey S. Na\(^{+}\)/H\(^{+}\) exchanger, pH regulation and cancer. *Recent Pat Anti-Canc.* 2013;8(1):85–99.

128. Chiang YH, Chou CY, Hsu KF, Huang YF, Shen MR. EGF upregulates Na\(^{+}\)-H\(^{+}\)cotransporter (NBCn1) function and expression by MEK/HOGT pathway. *Oncogene.* 2019;38(1):165–178. doi:10.1007/s10783-018-04863-0

129. Boedtkjer E. Na\(^{+}\)/H\(^{+}\) cotransporter NBCN1 accelerates breast carcinogenesis. *Cancer Metast Rev.* 2019;38(1–2):165–178. doi:10.1007/s10555-019-09784-7

130. Lee S, Mele M, Vahl P, Christiansen PM, Jensen VED, Boedtkjer E. Na\(^{+}\)/H\(^{+}\) cotransporter is functionally upregulated during human breast carcinogenesis and required for the inverted pH gradient across the plasma membrane. *Pflug Arch Eur J Physiol.* 2015;467(2):367–377. doi:10.1007/s00424-014-1524-0

131. Andersen AP, Samsoe-Petersen J, Oernbo EK, et al. The net acid excluders NHE1, NBCn1 and MCT4 promote mammary tumor growth through distinct but overlapping mechanisms. *Int J Cancer.* 2018;142(12):2529–2542. doi:10.1002/ijc.31276

132. Chandel V, Maru S, Kumar A, et al. Role of monocarboxylate transporters in head and neck squamous cell carcinoma. *Oncogene.* 2018;37(10):1345–1371. doi:10.1002/ijc.31276

133. Boedtkjer E, Bunch L, Pedersen SF. Physiology, pharmacology and pathophysiology of the pH regulatory transport proteins NHE1 and NBCn1: similarities, differences, and implications for cancer therapy. *Curr Pharm Des.* 2012;18(10):1345–1371. doi:10.2174/138161295904830

134. Lee S, Axelsen TV, Andersen AP, Pedersen SF, Vahl P, Pedersen ES. Boedtkjer E. Disrupting Na\(^{+}\), HCO\(^{3-}\) cotransporter NBCN1 (Slc4a7) delays murine breast cancer development. *Oncogene.* 2016;35(16):2112–2122. doi:10.1038/onc.2015.273

135. Lee S, Axelsen TV, Jesse N, Pedersen SF, Vahl P, Boedtkjer E. Na\(^{+}\), HCO\(^{3-}\) cotransporter NBCN1 (Slc4a7) delays murine breast cancer development. *Oncogene.* 2018;37(41):5569–5584. doi:10.1038/s41388-018-0353-6

136. Lin L, Wang S, Deng H, et al. Endogenous labile iron pool-mediated free radical generation for cancer chemodynamic therapy. *J Am Chem Soc.* 2020;142(16):15320–15330. doi:10.1021/jacs.0c04650

137. Liu Y, Zhen WY, Wang YH, et al. One-dimensional FeP acts as a fenton agent in response to NIR II light and ultrasound for deep tumor synergetic theranostics. *Angewandte Chemie.* 2019;58(58):2407–2412. doi:10.1002/anie.201813702

138. Liu X, Liu Y, Wang J, Wei T, Dai Z. Mild hyperthermia-enhanced enzyme-mediated tumor cell chemodynamic therapy. *ACS Appl Mater Interfaces.* 2019;11(26):23065–23071. doi:10.1021/acsami.9b08257

139. Wu H, Chen F, Gu D, You C, Sun B. A pH-activated autocatalytic nanoreactor for self-boosting Fenton-like chemodynamic therapy. *Nanoscale.* 2020;12(33):17319–17331. doi:10.1039/D0NR03155F

140. Xu X, Zeng F, Yang X, et al. A honeycomb-like bismuth/manganese oxide nanoparticle with mutual reinforcement of internal and external responses for triple-negative breast cancer targeted therapy. *Adv Healthc Mater.* 2021;10:e2100518. doi:10.1002/adhm.202100518

141. Su JJ, Lu S, Wei Z, et al. Biocompatible inorganic nanoagent for efficient synergetic tumor treatment with augmented antitumor immunity. *Small.* 2022;18(16):e2200897

142. Guo Y, Jia HR, Zhang X, et al. A glucose/oxygen-exhausting nanoreactor for starvation- and hypoxia-activated sustainable and cascade chemo-chemodynamic therapy. *Small.* 2020;16(31):e2000897. doi:10.1002/smll.202000897

143. Zhang L, Yang Z, He W, Ren J, Wong CY. One-pot synthesis of a self-reinforcing cascade bioreactor for combined photodynamic/chemodynamic therapy. *J Colloid Interface Sci.* 2021;599:543–555. doi:10.1016/j.jcis.2021.03.173

144. Zhao PR, Tang ZM, Chen XY, et al. Ferrous-cysteine-phosphothionstate nanoagent with neutral pH fenton reaction activity for enhanced cancer chemodynamic therapy. *Mater Horiz.* 2019;6(2):369–374. doi:10.1039/C8MH01176A

145. Zhang HL, Li JJ, Chen Y, et al. Magneto-electrically enhanced intracellular catalysis of FeP-FeC heterostructures for chemodynamic therapy. *Adv Mater.* 2021;33(17):2100472. doi:10.1002/adma.202100472
148. Meng X, Chen L, Lv R, Liu M, He N, Wang Z. A metal-phenolic network-based multifunctional nanocomposite with pH-responsive ROS generation and drug release for synergistic chemodynamic/photothermal/chemo-therapy. *J Mater Chem B*. 2020;8(10):2177–2188. doi:10.1039/D0TB00008F

149. Liu Y, Chi SY, Cao Y, Liu ZH. Glutathione-responsive biodegradable core-shell nanoparticles that self-generate H$_2$O$_2$ and deliver doxorubicin for chemo-chemodynamic therapy. *ACS Appl Nano Mater*. 2020;3(2):2592–2602. doi:10.1021/acsanm.0c03490

150. Wang Y, Song M. pH-responsive cascaded nanocatalyst for synergistic like-starvation and chemodynamic therapy. *Colloids Surf B Biointerfaces*. 2020;192:111029. doi:10.1016/j.colsurfb.2020.111029

151. Chen J, Wang X, Zhang Y, et al. A redox-triggered C-centered free radicals nanogenerator for self-enhanced magnetic resonance imaging and chemodynamic therapy. *Biomaterials*. 2021;266:120457. doi:10.1016/j.biomaterials.2020.120457

152. Cui Y, Chen X, Cheng Y, et al. CuWO$_4$ nanodots for NIR-induced photodynamic and chemodynamic synergistic therapy. *Acs Appl Nano Mater*. 2020;13(19):22150–22158. doi:10.1021/acsnano.0c05290

153. Hu T, Yan L, Wang Z, et al. A pH-responsive ultrathin Cu-based nanoplatform for specific photothermal and chemodynamic synergistic therapy. *Chem Sci*. 2021;12(7):2594–2603. doi:10.1039/D0SC0742C

154. Tao Q, He GH, Ye S, et al. Mn doped Prussian blue nanoparticles for T-1/T-2 MR imaging, PA imaging and Fenton reaction enhanced mild temperature photothermal therapy of tumor. *J Nanobiotechnol*. 2021;20(1). doi:10.1186/s12951-021-01235-2

155. Peng H, Qin YT, Feng YS, He XW, Li WY, Zhang YK. Phosphate-degradable nanoparticles based on metal-organic frameworks for chemo-starvation-chemodynamic synergistic antitumor therapy. *Acs Appl Mater Interfaces*. 2021;13(31):37713–37723. doi:10.1021/acsami.1c10816

156. Zheng RX, Cheng Y, Qi F, et al. Biodegradable copper-based nanoparticles augmented chemodynamic therapy through deep penetration and suppressing antioxidant activity in tumors. *Adv Healthc Mater*. 2021;10(14):2100412. doi:10.1002/adhm.202100412

157. Lin XH, Zhu R, Hong ZZ, et al. GSH-responsive radiosensitizers with deep penetration ability for multimodal imaging-guided synergistic radio-chemodynamic cancer therapy. *Adv Funct Mater*. 2021;31(24):2101278. doi:10.1002/adfm.202101278

158. Fu S, Yang R, Ren J, et al. Catalytically active CoFe$_2$O$_4$ nanoflowers for augmented sonodynamic and chemodynamic combination therapy with elicitation of robust immune response. *Acs Nano*. 2021;15(7):11953–11969. doi:10.1021/acs.nanolett.1c03128

159. Zhang X, He C, Chen Y, et al. Cyclic reactions-mediated self-supply of H$_2$O$_2$ and O$_2$ for cooperative chemodynamic/starvation cancer therapy. *Biomaterials*. 2021;275:120987. doi:10.1016/j.biomaterials.2021.120987

160. Yang BC, Liu QY, Yao XX, et al. FePt@MnO-based nanotheranostic platform with acidity-triggered dual-ions release for enhanced MR imaging-guided ferroptosis chemodynamic therapy. *Acs Appl Mater Inter*. 2020;11(42):38395–38404. doi:10.1021/acsami.9b11353

161. Wang YN, Song D, Zhang WS, Xu ZR. Enhanced chemodynamic therapy at weak acidic pH based on g-C$_3$N$_4$-supported hemin/Au nanoplat-form and cell apoptosis monitoring during treatment. *Colloid Surface B*. 2021;197:111437. doi:10.1016/j.colsurfb.2020.111437

162. Li T, He F, Liu B, et al. In situ synthesis of FeOCl in hollow dendritic mesoporous organosilicon for ascorbic acid-enhanced and MR imaging-guided chemodynamic therapy in neutral pH conditions. *Acs Appl Mater Inter*. 2020;12(51):56886–56897. doi:10.1021/acsami.0c03430

163. Dong SM, Dong YS, Jia T, et al. Sequential catalytic, magnetic targeting nanoplatinum for synergistic photothermal and NIR-enhanced chemodynamic therapy. *Chem Mater*. 2020;32(23):9868–9881. doi:10.1021/acs.chemmater.9b05170